HH185

N/A

Report date: 2025/05/21 20:00:31
NME

Base Information

Drug NameHH185
Drug Alias Name3-D185HH-1853D1853D-185
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 3 antagonistsFibroblast growth factor receptor 1 antagonistsFibroblast growth factor receptor 2 antagonists +[4] 
TargetsFibroblast growth factor receptor 1Fibroblast growth factor receptor 3Fibroblast growth factor receptor 2 +[4] 
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShangHai HaiHe Biopharma Co LtdShanghai Institute Of Materia Medica, Chinese Academy Of SciencesShanghai Medicilon Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesThinkti (Beijing) Pharmaceutical Technology Co LtdShanghai Institute Of Materia Medica, Chinese Academy Of SciencesShangHai HaiHe Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A